Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CD19-CAR-DNT cells in relapsed/refractory autoimmune diseases
NCT06316076Phase 1Recruiting
- Sponsor
- Renji Hospital
- Start
- Oct 2023
- Primary completion
- Jun 2024
- Modality
- CAR-T Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of RJMty19 in systemic lupus erythematosus (SLE), Antineutrophil cytoplasmic antibody-associated vasculitis (AAV), idiopathic inflammatory myopathies (IIM) and 1 more, sponsored by Renji Hospital. Primary endpoints: Dose-Limiting Toxicity at 28 days, Maximum Tolerated Dose at 28 days and 1 more. Started Oct 2023; status: recruiting.
02
Drugs
RJMty19
03
Conditions
systemic lupus erythematosus (SLE)Antineutrophil cytoplasmic antibody-associated vasculitis (AAV)idiopathic inflammatory myopathies (IIM)systemic sclerosis (SSc)
Beyond the preview
Go deeper on NCT06316076.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06316076.